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Excessive alcohol consumption is associated with reduced brain volume and cognition. While the mechanisms by which ethanol
induces these deleterious effects in vivo are varied most are associated with increased inflammatory and oxidative processes. In
order to further characterise the effect of acute ethanol exposure on oxidative damage and NAD+ levels in the brain, human U251
astroglioma cells were exposed to physiologically relevant doses of ethanol (11mM, 22mM, 65mM, and 100mM) for ≤ 30 minutes.
Ethanol exposure resulted in a dose dependent increase in both ROS and poly(ADP-ribose) polymer production. Significant
decreases in total NAD(H) and sirtuin 1 activity were also observed at concentrations ≥ 22mM. Similar to U251 cells, exposure
to ethanol (≥22mM) decreased levels of NAD(H) in primary human astrocytes. NAD(H) depletion in primary astrocytes was
prevented by pretreatment with 1 𝜇M of lycopene for 3.5 hours. Unexpectedly, in U251 cells lycopene treatment at concentrations
≥ 5 𝜇M resulted in significant reductions in [NAD(H)]. This study suggests that exposure of the brain to alcohol at commonly
observed blood concentrations may cause transitory oxidative damage which may be at least partly ameliorated by lycopene.
1. Introduction
While the consequence of light-to-moderate alcohol con-
sumption on brain health is currently debated within the
literature, excessive consumption is generally agreed upon
to reduce both brain volume and cognition [1, 2]. The
ways in which ethanol may impose these deleterious effects
are varied and although not completely understood most
appear to be associated with an increase in inflammatory
and oxidative processes. Within the brain this is thought
to occur via several pathways including proinflammatory
cytokine inducible nitric oxide synthase activation [3],
decreased antioxidant enzyme activity [4], increased NMDA
receptor sensitivity [5], cytochrome P450 2El induction
[6], increased prostanoid production through cyclooxyge-
nase/phospholipase A2 mechanisms [7, 8], and hydroxyethyl
radical formation [9].
The shift in redox balance following ethanol exposure is
known to cause a number of morphological and functional
brain cell alterations including an increase in DNA nicks
and breaks and subsequent activation of poly(ADP-ribose)
polymerase (PARP) [10]. Importantly, in order to facilitate
DNA repair, PARP uses nicotinamide adenine dinucleotide
(NAD+) as a substrate to form poly(ADP-ribose) subunits.
Under conditions of mild-to-moderate DNA damage this
process promotes cell survival [11]. However overactivation
of PARP, in response to extreme DNA damage, as may
occur following alcohol consumption [12, 13], can cause both
neuronal and astroglial death as a consequence of decreased
ATP production due to NAD+ depletion [14, 15].
The importance of maintaining adequate concentrations
of the ubiquitous NAD+ molecule for cellular health is the
subject of increased interest. In addition to its role in gener-
ating cell energy (i.e., ATP) and metabolism there are several
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enzymes, in addition to PARP, which use NAD+ as their
substrate. The sirtuins (SIRT), a family of protein deacety-
lases, are one such group that depend on NAD+ for their
activity [16]. Known for their role in cellular senescence and
aging, modulation of sirtuin activity via NAD+ dependent
mechanisms has been shown to impact the course of several
neurodegenerative diseases [17–19]. Sirtuins have also been
identified as key inhibitors of microglia-mediated inflam-
mation and oxidative damage [20]. Considered together,
evidence suggests that, in order to maintain healthy brain
cell activity through sufficient cellular energy production
and appropriate PARP and SIRT activity, sufficient stores of
NAD+ must be maintained.
Early investigations of the effect of ethanol on NAD+
metabolism have shown that excessive acute/chronic exp-
osure can significantly decrease NAD+ stores in both
Drosophila and rats [21, 22]. In line with this work we
recently reported an inverse association between alcohol con-
sumption (≥0-1 standard drink/day) and total nicotinamide
adenine dinucleotide (NAD(H)) levels in the human CSF
of free living adults [23]. Importantly in this same cohort,
we also reported that increased levels of CSF [NAD(H)]
were associated with high plasma concentrations of the diet
derived phytochemical, lycopene [24].
Lycopene, a naturally occurring carotenoid found abun-
dantly in red coloured fruits and vegetables, is a potent
quencher of singlet oxygen (1O
2
) [25]. In hepatic HepG2
cells lycopene has been shown to attenuate alcohol-induced
oxidative stress [26], in Mongolian gerbils, to protect
the hippocampus against oxidative damage after ischemia-
reperfusion [27]. Interestingly lycopene has also been
demonstrated in murine models to restore PARP and SIRT
activity following oxidative stimuli [28, 29]. Collectively,
these findings suggest that lycopene may potentially act as a
neuroprotective agent by attenuating reactive oxygen species
(ROS) production and reducing oxidative damage, though
these effects are yet to be demonstrated in human brain tissue.
In this study, we investigated the effect of acute ethanol
exposure, at commonly observed blood alcohol concentra-
tions (BAC), on oxidative processes and NAD(H) levels in
cultured human brain glial cells. We demonstrated that at
physiologically relevant levels lycopene is protective against
acute ethanol toxicity by suppressing oxidative damage and
subsequent PARP activity and thus preserving [NAD(H)].
2. Materials and Methods
2.1. Tissue Preparation and Cell Culture. Sixteen-to-nineteen
week foetal brains were collected following therapeutic ter-
mination with informed consent. Mixed brain cultures were
prepared and maintained according to ethical approval by
HREC 08284, using a protocol previously described [30].
Astrocytes were prepared from the mixed brain cell
cultures using a protocol previously described [31]. The
human astroglioma U251 cell line was also used. Cells were
cultured in RPMI 1640media (Sigma-Aldrich) supplemented
with 20% foetal bovine serum (Gibco), 1% L-glutamine
(Gibco), and 1% antibiotic-antimycotic (Invitrogen) at 37∘C
in a humidified incubator containing 5% CO
2
and 95% air.
Cells were seeded into 96-well culture plates at a density of 2
× 104 (astrocytes; P1–5) or 3 × 104 (U251; P1–20) cells/well at
least 12 hours prior to experimentation.
2.2. Cell Treatment. Cells were exposed to physiologically
relevant concentrations of ethanol (11mM, BAC 0.05%;
22mM, BAC 0.1%; 65mM, BAC 0.3%; and 100mM, BAC
0.5%) for either 10, 15, or 30 minutes at 37∘C. All treatments
were administered as solutions in RPMI 1640 phenol red-free
media, adjusted to a pH 7-8, and prepared immediately before
dosing.
Lycopene (Sigma-Aldrich) was dissolved in tetrahydro-
furan (Sigma-Aldrich) containing 0.025% butylated hydrox-
ytoluene (Sigma-Aldrich) to inhibit formation of peroxides.
This stock solution was prepared with minimal exposure to
air and light and stored at −80∘C. Immediately before the
experiments, the lycopene stock solutionwas diluted inRPMI
1640 phenol red-free media (Sigma-Aldrich), homogenised,
and filtered at 0.45 𝜇m. For lycopene dosage experiments cells
were exposed to physiologically relevant concentrations of
lycopene (0.1𝜇M, 1.0 𝜇M, 5 𝜇M, and 10 𝜇M) for 3.5 hours
at 37∘C. To investigate the influence of lycopene on ethanol
mediated effects, cells were exposed to 1.0 𝜇M of lycopene
for 3.5 hours at 37∘C. This dosage was chosen based on
previously published data from our group indicating that
normal physiological concentrations of lycopene within the
central nervous system are < 1.5 𝜇M [24]. In addition high
concentrations of lycopene have been shown to induce
toxicity, particularly under prooxidant conditions, such as
those produced during ethanol treatment [32, 33]. The
amount of tetrahydrofuran/butylated hydroxytoluene vehicle
in the culture medium was never greater than 0.1% (v/v), a
concentration that has previously been shown not to affect
cell number, viability, or ROS production [34].
2.3. Reactive Oxygen Species. Intracellular ROS were quan-
tified using the cell-permeable fluorogenic probe 2󸀠,7󸀠-
dichlorodihydrofluorescein diacetate (DCFH-DA) according
to a method adapted from the OxiSelect Intracellular ROS
Assay Kit (Green Fluorescence) (Cell Biolabs Inc.). Briefly,
cells were cultured in a 96-well cell plate and then preincu-
bated with DCFH-DA for 1 hour. The DCFH-DA diffuses
into the cells where it is deacetylated by cellular esterases
to nonfluorescent 2󸀠,7󸀠-dichlorodihydrofluorescein. Cultures
were then exposed to the appropriate treatment after which
cells were lysed using a 1% Triton-X lysis buffer. The fluores-
cence intensity was then measured at excitation/emission =
485/528 nm.
In the presence of ROS 2󸀠,7󸀠-dichlorodihydrofluorescein
is rapidly oxidized to highly fluorescent 2󸀠,7󸀠-dichlorodihy-
drofluorescein. The resulting fluorescent signal is therefore
proportional to the level of reactive oxygen species generated
within the cell. Results are expressed as the change in
absorbance relative to control.
2.4. Poly(ADP-Ribose) Polymers. Poly(ADP-ribose) poly-
mers were quantified as a measure of PARP activity using
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the In-Cell ELISA Detection Kit (Thermo Scientific), accord-
ing to the manufacturer’s instructions. Briefly to quantify
poly(ADP-ribose) polymers, cells were fixed after the appro-
priate treatment(s) using 4% formaldehyde (Sigma-Aldrich)
and incubated at 4∘C overnight in the presence of diluted
(1 : 1000) anti-PADPR [10H] antibody (Abcam). Following
the addition of a horseradish peroxidase conjugate and
3,3󸀠,5,5󸀠-tetramethylbenzidine substrate the absorbance was
measured at 450 nm. The number of cells per well was then
determined using the Janus Green Whole-Cell Stain. Results
are expressed as the change in absorbance relative to control
and adjusted for variations in cell number.
2.5. Sirtuin 1 Activity. As the experiments conducted in this
study were acute (i.e., ≤ 30 minutes) and therefore unlikely to
alter either protein or gene expression levels, only SIRT1 activ-
ity was quantified using the SensoLyte Green SIRT1 Assay
Kit: Fluorimetric (AnaSpec) according to the manufacturer’s
instructions. In this protocol, the deacetylation of substrate
by SIRT1 within the cell homogenate results in the generation
of a fluorophore that was detected after the addition of a




= 490 nm/520 nm. Results are
expressed as the change in absorbance relative to control and
adjusted for variations in protein content.
2.6. NAD(H). Intracellular NAD(H) levels were measured
using the thiazolyl blue microcycling assay established by
Bernofsky and Swan [35] and adapted for a 96-well plate
format by Grant and Kapoor [36]. In this assay NAD+
present within the cell homogenate is converted to NADH,
which in turn reduces thiazolyl blue tetrazolium bromide
to a purple formazan product, which absorbs at 570 nm.
The reaction mixture that causes this conversion consisted
of phenazine methosulfate (2mM; Sigma-Aldrich), thiazolyl
blue tetrazolium bromide (0.5mM; Sigma-Aldrich), ethanol
(0.6M), bicine (120mM, pH 7.8; Sigma-Aldrich), and alco-
hol dehydrogenase (1mg/mL; Sigma-Aldrich). Results are
expressed as the change in absorbance relative to control and
adjusted for variations in protein content.
2.7. Total Protein. Results for SIRT1 activity and NAD(H)
assays are adjusted for variations in protein content, quan-
tified using the Bradford protein assay. In this protocol
Coomassie Brilliant Blue G-250 (Bradford reagent; Sigma-
Aldrich) binds to protein causing a shift in the absorption
maximum of the dye from 465 nm to 595 nm which was
measured spectrophotometrically.
2.8. Statistical Analysis. Statistical analyses were performed
using SPSS version 16.0 and GraphPad Prism version 5 for
Windows. Data is presented as the mean ± SEM. Significant
differences between treatments were assessed using one-way
analysis of variance with post hoc Tukey Multiple Compar-
isons Test after verification of normality within the data set.
If the data was not normally distributed the nonparametric
Kruskal-Wallis with post hoc Dunn’s Multiple Comparisons
Test was employed. 𝑃 values are provided throughout with
test significance set at 𝑃 value ≤ 0.05.
3. Results
3.1. Ethanol Increases the Production of ROS in U251 Cells.
Exposure to 11mM, 22mM, 65mM (𝑃 < 0.01), and 100mM
(𝑃 < 0.001) of ethanol for 10 minutes increased intracellular
ROS production above control by 7.9 ± 3.9%, 11.5 ± 4.1%,
16.6 ± 3.6%, and 26.7 ± 5.8%, respectively; however sta-
tistically significant differences were only observed following
exposure to 65mM and 100mM of ethanol (Figure 1(a)).
3.2. Ethanol Increases the Production of Poly(ADP-Ribose)
Polymers in U251 Cells. Exposure to 11mM (𝑃 < 0.001),
22mM (𝑃 < 0.001), 65mM (𝑃 < 0.001), and 100mM (𝑃 <
0.01) of ethanol for 15 minutes increased poly(ADP-ribose)
polymer production above control by 8.7 ± 3.1%, 6.2 ± 1.7%,
4.8 ± 1.1%, and 4.5 ± 1.0%, respectively (Figure 1(b)).
3.3. Ethanol Decreases Total NAD(H) in U251 Cells. Expo-
sure to ethanol for 30 minutes was found to decrease the
concentration of intracellular NAD(H) in the U251 cell line.
Exposure to 22mM (𝑃 < 0.01), 65mM (𝑃 < 0.001),
and 100mM (𝑃 < 0.001) of ethanol decreased intracellular
NAD(H) levels compared to control by 10.4 ± 2.2%, 17.0 ±
3.3%, and 21.8 ± 3.6%, respectively (Figure 1(c)).
3.4. Ethanol Decreases SIRT1 Activity in U251 Cells. Exposure
to ethanol for 30minuteswas found to decrease SIRT1 activity
in the U251 cell line. Exposure to 22mM (𝑃 < 0.001),
65mM (𝑃 < 0.001), and 100mM (𝑃 < 0.001) of ethanol
for 30 minutes decreased SIRT1 activity by 29.2 ± 5.4%, 40.2
± 3.1%, and 42.0 ± 4.2%, respectively, compared to control
(Figure 1(d)).
3.5. Lycopene Decreases Total NAD(H) in U251 Cells. Expo-
sure of U251 cells to 0.1 𝜇M, 1 𝜇M, 5 𝜇M (𝑃 < 0.05), and
10 𝜇M (𝑃 < 0.05) of lycopene for 3.5 hours resulted in
a decrease in NAD(H) levels by 9.8 ± 7.0%, 20.2 ± 5.2%,
25.2 ± 6.5%, and 23.6 ± 6.2%, respectively (Figure 2(a)).
However statistically significant reductions in NAD(H) were
only observed following exposure to ≥ 5 𝜇M of lycopene.
3.6. Effect of Lycopene on Total NAD(H) in Primary Astrocytes.
Unlike U251 cells, exposure to 0.1 𝜇M of lycopene for 3.5
hours did not affect NAD(H) levels in primary astrocytes.
Although an apparent 10.4 ± 5.2% increase in [NAD(H)],
compared to control, was observed after exposure to 1.0𝜇M
of lycopene, this was not statistically significant. Exposure to
5 𝜇M (𝑃 < 0.01) and 10 𝜇M (𝑃 < 0.05) of lycopene was
found to reduce [NAD(H)] by 32.9 ± 10.7% and 27.2 ± 5.8%,
respectively, compared to control (Figure 2(b)).
3.7. Ethanol Decreases Total NAD(H) in Primary Astrocytes.
Similar to U251 cells, exposure to ethanol for 30 minutes
decreased the concentration of intracellular NAD(H) in
primary astrocytes (Figure 3). Exposure to 22mM (𝑃 < 0.05),
65mM (𝑃 < 0.01), and 100mM (𝑃 < 0.001) of ethanol
decreased NAD(H) levels, compared to control, by 24.4 ±
4.6%, 31.0 ± 4.0%, and 40.6 ± 8.2%, respectively.






























































































Figure 1: Ethanol exposure of U251 cells for ≤ 30 minutes, effects on (a) reactive oxygen species production, (b) generation of poly(ADP-






































Control 0.1 1.0 5.0 10.0
Lycopene (𝜇M)
(b)
Figure 2: The effect of lycopene on NAD(H) concentrations in (a) U251 cells and (b) primary human astrocytes after 3.5 hours. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01. Data are presented as mean ± SEM.






















Figure 3: The effect of ethanol on NAD(H) concentrations in
primary human astrocytes after 30 minutes. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01,
∗∗∗





































































Figure 4: Pretreatment of primary human astrocytes with lycopene
(1 𝜇M) for 3.5 hours preserved the ethanol (22mM, 65mM) facili-
tated decrease in NAD(H) concentrations. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01,
and ∗∗∗𝑃 < 0.001. Data are presented as mean ± SEM.
3.8. Lycopene Ameliorates Ethanol Induced NAD(H) Depletion
in Primary Astrocytes. In order to determine if lycopene
could prevent the ethanol induced depletion in [NAD(H)],
primary astrocytes were pretreated with 1 𝜇M of lycopene
for 3.5 hours. Pretreated cells were then exposed to either
22mM or 65mM concentrations of ethanol for 30 minutes.
Pretreated primary astrocytes exposed to either 22mM (𝑃 <
0.001) or 65mM (𝑃 < 0.01) concentrations of ethanol
maintained intracellular NAD(H) levels at 104.4 ± 5.7% and
95.0 ± 7.4%, respectively (Figure 4).
4. Discussion
There is strong evidence to suggest that excessive acute
and/or chronic alcohol intake results in damage to the
brain. Nevertheless the mechanisms underlying ethanol’s
deleterious effects are not completely understood. In this
study we investigated the effect of acute ethanol exposure,
at physiologically relevant concentrations, on oxidative stress
and NAD(H)-related biochemistry in human astrocytes and
sought to determine if any ethanol induced reductions in
[NAD(H)] could be ameliorated by lycopene. We found
that acute ethanol exposure dose dependently increased the
production of ROS in U251 cells. This result is in line with
several previous in vitro and in vivo studies where both
acute and chronic ethanol exposure were found to increase
oxidative activity in neurons and astrocytes as well as various
cerebral regions [37–39]. However, while the majority of
previous studies were conducted using high ethanol doses,
the results from the present study suggest that ethanol may, at
least temporarily, enhance oxidative activity within exposed
brain cells at physiologically relevant concentrations.
Ethanol exposure was also observed to cause a significant
increase inU251 cell PARP activity.This effectwas observed at
concentrations as low as 11mM, a dose equivalent to a blood
alcohol concentration of 0.05%, attained by consumption of
approximately two standard drinks. Although few reports
detail ethanol’s ability to induce astroglial DNAdamage in the
form that activates PARP, Cherian and colleagues previously
observed that ethanol treatment of neurons generates an
increase in DNA nicks which was associated with a marked
upregulation of PARP expression [10]. Consistent with these
findings a significant increase in poly(ADP-ribose) polymers
was apparent in the present study after only 15 minutes of
exposure to 11mM of EtOH reflecting the initiation of DNA
repair in response to ethanol induced oxidative damage and
DNA strand breaks.
As previously discussed, in order to facilitate DNA repair,
PARP uses NAD+ as its key substrate. Accordingly, we
observed a dose dependent relationship between increasing
ethanol concentrations and decreased [NAD(H)]. While
research investigating the effect of ethanol on NAD(H) is
scarce these results are consistent with previous reports by
us showing reduced levels of [NAD(H)] in CSF of free living
individuals who consume ≥ 0-1 standard drink of alcohol
per day [23]. Early investigations in which NAD+ levels were
observed to decrease in response to ethanol stress further
corroborate the findings from the present study [21, 22].
The sirtuins proteins are a family of enzymes that, like
PARP, use NAD+ as their primary substrate. While ethanol
exposure has previously been shown to reduce SIRT1 activity
in the murine liver [40, 41] and is thus hypothesised to be
an important target of ethanol action, surprisingly no known
study has previously investigated the effect of ethanol on SIRT
activity in the brain or its cells. In this study acute ethanol
exposure was found to reduce SIRT1 activity in U251 cells
in a dose dependent manner. This novel effect is consistent
with the observed PARP facilitated NAD+ depletion. While
a decrease in SIRT1 activity may also occur as a result of an
ethanol induced reduction in SIRTprotein synthesis [42], this
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is unlikely to have occurred in this study due to the short (≤
30minutes) duration of ethanol exposure. Further research is
required to identify the precise mechanism involved.
Considered together these findings indicate that acute
ethanol exposure (≤ 30 minutes), at physiologically relevant
concentrations, increases ROS production in U251 cells lead-
ing to an increase in PARP activity, presumably in response
to DNA damage, and a subsequent decrease in NAD(H) and
SIRT activity.
We then sought to determine if the ethanol induced shift
in redox balance and consequential decrease in NAD(H)
stores could be ameliorated by known diet derived antioxi-
dants like lycopene, a phytonutrient. Unexpectedly, exposure
of U251 cells to lycopene resulted in a dose dependent
decrease in [NAD(H)], suggesting a reduction in cell viability.
Though this affect is not known to have been previously
observed in these astroglioma U251 cells, this data is con-
sistent with reports by others showing that lycopene can
induce cell cycle arrest and increase apoptosis in cancer
cell lines of the breast, colon, and prostate [43]. While
the finding from the present study supports the proposal
that lycopene may be protective against various cancers,
further investigation is required to determine its therapeutic
potential and was beyond the scope of this study. To more
effectively investigate whether lycopene could be protective
against ethanol induced damage in brain cells, we again
tested this hypothesis in cultures of primary human astro-
cytes.
In contrast to the detrimental effect of lycopene on
U251 cells, exposure of primary astrocytes to commonly
observed blood lycopene concentrations (≤ 1 𝜇M) [24]
was not found to alter NAD(H) levels. Exposure to
supraphysiological concentrations (≥ 5 𝜇M) did however
result in a reduction in [NAD(H)]. This is consistent
with results from an investigation by Qu and colleagues,
where primary neuron viability was not observed to sig-
nificantly decrease until a lycopene dosage of 10 𝜇M was
applied, although nonsignificant reductions were observed
following exposure to 5 𝜇M [32]. Similarly, albeit in a
human colon cancer cell line (HT29), Lowe found that
lycopene only afforded protection against DNA damage
(induced by xanthine/xanthine oxidase) at relatively low
concentrations (1–3𝜇M). At higher concentrations (4–
10 𝜇M), the ability to protect cells against such oxidative
damage was rapidly lost, with the presence of lycopene
instead appearing to increase the extent of DNA damage
[33].
A number of mechanisms have been suggested as reasons
for lycopene’s toxicity at high concentrations. In conditions
of enhanced oxidative potential lycopene has been shown
in human fibroblasts to act as a prooxidant, increasing lipid
peroxidation at dosages ≥ 10 𝜇M [44]. Unlike low dose
lycopene supplementation (1.1mg/kg), high dose supplemen-
tation (3.3mg/kg) has also been shown to significantly induce
hepatic CYP2E1 protein (a known producer of ROS and an
ethanol metaboliser), TNF-𝛼 mRNA, and the incidence of
inflammatory foci in alcohol fed rats [45]. While further
in vivo research is required, these studies indicate that at
supraphysiological concentrations lycopene may potentiate
toxicity and suggest a need for caution when supplement-
ing, particularly among individuals with enhanced oxidative
potential.
Despite some evidence suggesting potential toxicity of
lycopene at high doses, the antioxidant properties of lycopene
are well documented [25–27] and have been extensively
reviewed by others [46–49]. Indeed in the present study
pretreatment of primary astrocytes with 1𝜇Mof lycopenewas
found to preserve intracellular [NAD(H)] following acute
ethanol exposure.This is consistent with a previous report by
Xu et al. [26] who demonstrated that lycopene can prevent
ethanol induced oxidative stress in hepatic cells, as well as in
vivo data by our laboratory of a positive association between
human plasma lycopene concentrations (0.4 ± 0.3 𝜇M) and
CSF [NAD(H)] [24]. Considering the evidence we speculate
that this novel finding is most likely the consequence of
lycopene’s potent ROS quenching ability.
Out of the 600 known carotenoids, lycopene is considered
one of the most efficient singlet oxygen quenchers [25].
Lycopene is also known to effectively scavenge hydroxyl
radicals, capable of abstracting a hydrogen atom from ethanol
resulting in the production of 1-hydroxyethyl, as well as
superoxide anions and hydroperoxides, both of which are
produced during ethanol metabolism and are, at least par-
tially, responsible for ethanol’s adverse effects [50, 51]. In
addition to directly interacting with ROS, lycopene has
been shown to inhibit oxidative damage by modulating ROS
generating enzymes (such as nicotinamide adenine dinu-
cleotide phosphate-oxidase, inducible nitric oxide synthase,
cytochrome P450 enzymes, and cyclooxygenase-2) and by
activating protective/antioxidant Phase II enzymes (includ-
ing heme oxygenase-1, NAD(P)H dehydrogenase quinone 1,
and glutathione S-transferase) [52–56].
5. Conclusions
In summary, results from this study indicate that acute
ethanol exposure, at physiologically relevant concentrations,
increases oxidative damage in U251 cells, resulting in upreg-
ulation of PARP activity and consequently a significant
decrease in intracellular levels of its substrate NAD(H), a
molecule critical for cellular health. A novel dose depen-
dent relationship between ethanol exposure and reduced
concentrations of the protective NAD+ dependent enzyme
SIRT1 was also observed. Further investigation is required to
determine if this effect was solely the consequence of reduced
NAD+ availability. While data from this study suggests that
exposure of the brain to alcohol at commonly observed blood
concentrations may cause at least transitory oxidative dam-
age, the novel finding that lycopene can prevent the ethanol
induced reduction of astrocyte NAD(H) stores suggests that
this naturally occurring carotenoid, if present in the brain at
around 1 𝜇M,may at least partly ameliorate ethanol mediated
brain toxicity. Further research using mixed culture and
murine models is required to confirm this hypothesis.
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Abbreviations
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PARP: Poly(ADP-ribose) polymerase
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SIRT: Sirtuins.
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